OverviewSuggest Edit

Valbiotis is a company that develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients. The Company's “Nutrition Healthcare” approach seeks to develop tools designed to prevent type 2 diabetes, NASH (non-alcoholic steatohepatitis) and obesity. Valbiotis' mission is to help millions of people all over the world to live for a longer time, in good health.
TypePublic
Founded2014
HQPerigny, FR
Websitevalbiotis.com

Latest Updates

Employees (est.) (Sept 2020)36(+3%)
Share Price (Sept 2020)€4.5 (+2%)
Cybersecurity ratingAMore

Key People/Management at Valbiotis

Laurent Levy

Laurent Levy

Chairman of the Supervisory Board
Sébastien Peltier

Sébastien Peltier

CEO & Chairman of the Board of Directors
Jean Zetlaoui

Jean Zetlaoui

Medical Affairs and Clinical Development Consultant. Member of the Supervisory Board
Agnès Tixier

Agnès Tixier

Executive Director, Crédit Mutuel, Equity SCR. Member of the Supervisory Board
Jocelyn Pineau

Jocelyn Pineau

CFO & Director
Pascal Sirvent

Pascal Sirvent

CSO & Director
Show more

Valbiotis Office Locations

Valbiotis has an office in Perigny
Perigny, FR (HQ)
Zone Industrielle des 4 Chevaliers, Bâtiment 12F, Rue Paul Vatine
Show all (1)

Valbiotis Financials and Metrics

Valbiotis Revenue

Market capitalization (25-Sept-2020)

34.5m

Closing stock price (25-Sept-2020)

4.5
Valbiotis's current market capitalization is €34.5 m.
Show all financial metrics

Valbiotis Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Valbiotis Online and Social Media Presence

Embed Graph

Valbiotis Blogs

VALBIOTIS announces positive results from the Phase IIA clinical study of VALEDIA®, now the first product proven effective in people with prediabetes

The article VALBIOTIS announces positive results from the Phase IIA clinical study of VALEDIA®, now the first product proven effective in people with prediabetes first appeared on Valbiotis.

VALBIOTIS to present novel data about TOTUM-63 and metabolic diseases prevention at the 2019 scientific sessions of the American Diabetes Association

The article VALBIOTIS to present novel data about TOTUM-63 and metabolic diseases prevention at the 2019 scientific sessions of the American Diabetes Association first appeared on Valbiotis.

VALBIOTIS succeeds in the industrial production of VALEDIA®, a major scientific innovation for prediabetic people, in collaboration with the Pierre Fabre group

The article VALBIOTIS succeeds in the industrial production of VALEDIA®, a major scientific innovation for prediabetic people, in collaboration with the Pierre Fabre group first appeared on Valbiotis.

Congrès de l’American Association for the Study of Liver Disease

L’article Congrès de l’American Association for the Study of Liver Disease est apparu en premier sur Valbiotis.
Show more

Valbiotis Frequently Asked Questions

  • When was Valbiotis founded?

    Valbiotis was founded in 2014.

  • Who are Valbiotis key executives?

    Valbiotis's key executives are Laurent Levy, Sébastien Peltier and Jean Zetlaoui.

  • How many employees does Valbiotis have?

    Valbiotis has 36 employees.

  • Who are Valbiotis competitors?

    Competitors of Valbiotis include NovaVision, Foresight and Alseres Pharmaceuticals.

  • Where is Valbiotis headquarters?

    Valbiotis headquarters is located at Zone Industrielle des 4 Chevaliers, Bâtiment 12F, Rue Paul Vatine, Perigny.

  • Where are Valbiotis offices?

    Valbiotis has an office in Perigny.

  • How many offices does Valbiotis have?

    Valbiotis has 1 office.